Cause for concern in the use of non-steroidal anti-inflammatory medications in the community -a population-based study

被引:51
|
作者
Adams, Robert J. [1 ]
Appleton, Sarah L. [1 ]
Gill, Tiffany K. [2 ]
Taylor, Anne W. [2 ]
Wilson, David H. [1 ]
Hill, Catherine L. [1 ,3 ]
机构
[1] Univ Adelaide, Queen Elizabeth Hosp Campus, Hlth Observ, Woodville, SA, Australia
[2] Univ Adelaide, Populat Res & Outcomes Studies Unit, Adelaide, SA, Australia
[3] Queen Elizabeth Hosp, Rheumatol Unit, Woodville, SA 5011, Australia
来源
BMC FAMILY PRACTICE | 2011年 / 12卷
关键词
COX-2; inhibitors; Non-steroidal anti-inflammatory; chronic disease; cardiovascular risk; CARDIOVASCULAR RISK; GENERAL-PRACTICE; HEART-FAILURE; HEALTH; DRUGS; NSAIDS; OSTEOARTHRITIS; INDIVIDUALS; MANAGEMENT; INHIBITORS;
D O I
10.1186/1471-2296-12-70
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Non-steroidal anti-inflammatory (NSAID) medications are a common cause of reported adverse drug side-effects. This study describes the prevalence of non-steroidal anti-inflammatory (NSAID) use (other than low-dose aspirin) and the presence of co-existing relative contraindications to NSAID use and chronic conditions in a representative population sample. Methods: Data were analysed from 3,206 adults attending first follow-up of the North West Adelaide Health Study (NWAHS) in 2004 - 2006, a longitudinal representative population study. Medications were brought into study clinic visits by participants. Clinical assessment included measured blood pressure, kidney function, serum cholesterol, blood glucose. Questionnaires assessed demographics, lifestyle risk factors, physician-diagnosed chronic conditions. Data were weighted to census measures by region, age group, gender, and probability of selection in the household, to provide population representative estimates. Pearson's Chi-square tests determined significant differences in proportions. Multiple logistic regression was used to examine associations of socio-demographic characteristics with use of NSAIDs. Results: Of 3,175 participants, 357 (11.2%), and 16% of those aged > 55 years, reported using either non-specific NSAIDs or COX-2 inhibitors, other than low-dose aspirin. Among people using NSAIDs, 60.8% had hypertension, 30.8% had Stage 3 or higher chronic kidney disease, 17.2% had a history of cardiovascular disease (CVD) and 20.7% had a > 15% 10-year CVD risk. The prevalence of NSAID use among people with hypertension was 16%, with kidney disease 15.9%, and a history of CVD 20.0%. Among people taking diuretics, 24.1% were also taking NSAIDs, and of those taking medications for gastro-esophageal reflux, 24.7% were on NSAIDs. Prescription-only COX-2 inhibitors, but not other NSAIDs, were used more by people > 75 years than by 35-54 year olds (OR 3.7, 95% CI 2.0, 6.7), and also were more commonly used by people with hypertension, cardiac and kidney disease. Conclusions: There is a high prevalence of current NSAID use among groups at-risk for significant drug-related adverse events or who have major chronic conditions that are relative contraindications to NSAID use. Assessment of absolute risks regarding cardiovascular and kidney disease need to take into account use of medications such as NSAIDs. The potential to make a substantial impact on chronic disease burden via improved use of NSAIDs is considerable.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspinn non-steroidal anti-inflammatory medications
    Velentgas, Priscilla
    West, William
    Cannuscio, Carolyn C.
    Watson, Douglas J.
    Walker, Alexander M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (09) : 641 - 652
  • [32] Non-steroidal anti-inflammatory drugs and the heart
    Aneja, Ashish
    Farkouh, Michael E.
    HEART, 2011, 97 (07) : 517 - 518
  • [33] Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in the Netherlands
    Van der Linden, Michiel W.
    Gaugris, Sabine
    Kuipers, Ernst J.
    Van den Bemt, Bart J. F.
    van Herk-Sukel, Myrthe P. P.
    Herings, Ron M. C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 195 - 204
  • [34] Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis
    Ungprasert, Patompong
    Srivali, Narat
    Kittanamongkolchai, Wonngarm
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2015, 26 (09) : 685 - 690
  • [35] Non-steroidal anti-inflammatory drugs and cardiovascular risk: At crossroads
    Farkouh, Michael E.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (08) : 736 - 737
  • [36] Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs
    Anwar, Asif
    Anwar, Imran John
    Delafontaine, Patrice
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (08) : 726 - 735
  • [37] GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the treatment of pain in osteoarthritis
    Crichton, B
    Green, M
    CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (02) : 92 - 96
  • [38] Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals
    Fosbol, Emil Loldrup
    Kober, Lars
    Torp-Pedersen, Christian
    Gislason, Gunnar H.
    EXPERT OPINION ON DRUG SAFETY, 2010, 9 (06) : 893 - 903
  • [39] Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation
    Thomas, T
    Nadackal, TG
    Thomas, K
    NEUROREPORT, 2001, 12 (15) : 3263 - 3267
  • [40] Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study
    Ingrasciotta, Ylenia
    Sultana, Janet
    Giorgianni, Francesco
    Fontana, Andrea
    Santangelo, Antonio
    Tari, Daniele Ugo
    Santoro, Domenico
    Arcoraci, Vincenzo
    Perrotta, Margherita
    Ibanez, Luisa
    Trifiro, Gianluca
    PLOS ONE, 2015, 10 (04):